Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis

Abstract

Objective To evaluate pathological complete response as a surrogate endpoint for disease-free survival and overall survival in regulatory neoadjuvant trials of early stage breast cancer. Design Systematic review and meta-analysis. Data sources Medline, Embase, and Scopus to 1 December 2020. Eligibility criteria for study selection Randomised clinical trials that tested neoadjuvant chemotherapy given alone or combined with other treatments, including anti-human epidermal growth factor 2 (anti-HER2) drugs, targeted treatments, antivascular agents, bisphosphonates, and immune checkpoint inhibitors. Data extraction and synthesis Trial level associations between the surrogate endpoint pathological complete response and disease-free survival and overall survival. Methods A weighted regression analysis was performed on log transformed treatment effect estimates (hazard ratio for disease-free survival and overall survival and relative risk for pathological complete response), and the coefficient of determination (R 2 ) was used to quantify the association. The secondary objective was to explore heterogeneity of results in preplanned subgroups analysis, stratifying trials according treatment type in the experimental arm, definition used for pathological complete response (breast and lymph nodes v breast only), and biological features of the disease (HER2 positive or triple negative breast cancer). The surrogate threshold effect was also evaluated, indicating the minimum value of the relative risk for pathological complete response necessary to confidently predict a non-null effect on hazard ratio for disease-free survival or overall survival. Results 54 randomised clinical trials comprising a total of 32 611 patients were included in the analysis. A weak association was observed between the log(relative risk) for pathological complete response and log(hazard ratio) for both disease-free survival (R 2 =0.14, 95% confidence interval 0.00 to 0.29) and overall survival (R 2 =0.08, 0.00 to 0.22). Similar results were found across all subgroups evaluated, independently of the definition used for pathological complete response, treatment type in the experimental arm, and biological features of the disease. The surrogate threshold effect was 5.19 for disease-free survival but was not estimable for overall survival. Consistent results were confirmed in three sensitivity analyses: excluding small trials (<200 patients enrolled), excluding trials with short median follow-up (<24 months), and replacing the relative risk for pathological complete response with the absolute difference of pathological complete response rates between treatment arms. Conclusion A lack of surrogacy of pathological complete response was identified at trial level for both disease-free survival and overall survival. The findings suggest that pathological complete response should not be used as primary endpoint in regulatory neoadjuvant trials of early stage breast cancer.

Efficacy of neoadjuvant treatment with or without pertuzumab in patients with stage II and III HER2-positive breast cancer: a nationwide cohort analysis of pathologic response and 5-year survival

“…The prognostic value of pCR is found across breast cancer subtypes, but is highest in triple negative and HER2-positive breast cancer [ [20] , [21] , [22] ]. However, a large and more recent published meta-analysis including 54 randomized trials did not find a strong association between pCR and disease-free survival [ 23 ]. Although the analysis was not based on individual patient data and results were not stratified within HER2-positive subgroups the findings stress the need for supportive real-world evidence of survival benefit for agents approved and widely prescribed following trials powered for surrogate endpoints.…”

Triple-Negative Apocrine Breast Carcinoma Has Better Prognosis despite Poor Response to Neoadjuvant Chemotherapy

“…More significantly, our results showed that TNAC patients have a poor chemotherapy responsiveness and no benefit from chemotherapy in terms of BCSS. Previous studies showed that pCR can be used as a surrogate endpoint in TNBC patients receiving neoadjuvant chemotherapy, meaning that patients who reached pCR have better survival than those who did not reach pCR [ 35 , 36 , 37 , 38 , 39 , 40 ]. Among the four molecular subtypes of TNBC, the LAR group has the lowest pCR rate [ 11 ].…”

Implications of Oncology Trial Design and Uncertainties in Efficacy-Safety Data on Health Technology Assessments

“…When ascertaining the benefits of cancer medicines through HTA, improvements in surrogate measures would need to be translated into OS or QoL estimates, extrapolated over time and inform key metrics for HTA, including cost-effectiveness. Such transformation and extrapolation can add substantial uncertainty to the assessment, as their robustness is subject to the assumptions used and the selected methodologies [ 40 , 41 , 42 , 43 , 44 ]. For example, a methodology review assessing the validity of PFS as a surrogate endpoint for predicting OS in cancer clinical trials found wide heterogeneity in methods and reporting [ 29 ].…”